FOURTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENTShareholder Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
WHEREAS, the Company, GIC, the Key Holders, the WFOE, the HK Company, the Domestic Companies and the other parties thereto are each parties to the Series C Preferred Share Purchase Agreement dated as of January 31, 2019 (the “Purchase Agreement”);
Agreement for Power of AttorneyPower of Attorney • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories
This Agreement for Power of Attorney (this “Agreement”) is executed by and among the following Parties on October 21, 2019 in Beijing, the People’s Republic of China (“China” and for the purposes of this Agreement, excludes Hong Kong, Macau and Taiwan):
Equity Pledge AgreementEquity Pledge Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories
This Equity Pledge Agreement (this “Agreement”) is executed by and among the following Parties on October 21, 2019 in Beijing, the People’s Republic of China (“China” and for the purposes of this Agreement, excludes Hong Kong, Macau and Taiwan):
Exclusive Business Cooperation AgreementExclusive Business Cooperation Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories
This Exclusive Business Cooperation Agreement (hereinafter referred to as this “Agreement”) is executed by and between the following two Parties on October 21, 2019 in Beijing, the People’s Republic of China (“China” and for the purposes of this Agreement, excludes Hong Kong, Macau and Taiwan).
SERIES A+ PREFERRED SHARE PURCHASE AGREEMENTSeries A+ Preferred Share Purchase Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
Each of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein shall have the meaning set forth in Schedule III attached hereto.
Voting Proxy AgreementVoting Proxy Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories • Beijing
This Voting Proxy Agreement (this “Agreement”) is entered into by and between the parties as of October 21, 2019 in Beijing, People’s Republic of China (“PRC”, for the purpose of this Agreement, PRC shall not include Hong Kong, Macau and Taiwan):
Exclusive Option AgreementExclusive Option Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories
This Exclusive Option Agreement (hereinafter referred to as this “Agreement”) is executed by and among the following Parties on October 21, 2019 in Beijing, the People’s Republic of China (“China” and for the purposes of this Agreement, excludes Hong Kong, Macau and Taiwan):
SERIES B PREFERRED SHARE PURCHASE AGREEMENTSeries B Preferred Share Purchase Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
Each of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein shall have the meaning set forth in Schedule III attached hereto.
SERIES C PREFERRED SHARE PURCHASE AGREEMENTSeries C Preferred Share Purchase Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
Each of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein shall have the meaning set forth in Schedule III attached hereto.
SECOND SERIES B PREFERRED SHARE PURCHASE AGREEMENTSecond Series B Preferred Share Purchase Agreement • November 4th, 2019 • Burning Rock Biotech LTD • Services-medical laboratories • Hong Kong
Each of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein shall have the meaning set forth in Schedule II attached hereto.
